Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SRIDHAR GUDURI

Allopathic & Osteopathic Physicians Allergy & Immunology

NPI
1669436192
CMS profile
210894
Location
DUBLIN, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$2,126.47

75 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,020.47 73
Education $106.00 2

By paying entity

PY2025 · entire year · sorted by reported total

Page 2 of 2; records 51–75 of 75 matching records. This page contains 25 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SRIDHAR GUDURI

NPI 1669436192 · CMS profile ID 210894

Allopathic & Osteopathic Physicians / Allergy & Immunology

DUBLIN, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–75 of 75 matching records. This page contains 25 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1669436192?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SRIDHAR GUDURI, NPI 1669436192, CMS profile ID 210894. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–75 of 75 matching records. This page contains 25 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1669436192?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). SRIDHAR GUDURI, NPI 1669436192, CMS profile ID 210894. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–75 of 75 matching records. This page contains 25 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1669436192?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
SRIDHAR GUDURI, NPI 1669436192, CMS profile ID 210894, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–75 of 75 matching records. This page contains 25 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1669436192?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

75 matching records · $2,126.47 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 75 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–75 of 75.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Hikma Pharmaceuticals USA $15.7104/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248218330 CMS
AstraZeneca Pharmaceuticals LP $22.1704/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206538838 CMS
AstraZeneca Pharmaceuticals LP $111.5604/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206713657 CMS
GENZYME CORPORATION $9.6204/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233373558 CMS
PFIZER INC. $12.3504/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229067366 CMS
Pharming Healthcare, Inc. $18.4104/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200797983 CMS
GENZYME CORPORATION $11.7303/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233373538 CMS
GENZYME CORPORATION $11.8603/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233373534 CMS
Optinose US, Inc. $17.7903/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1163254242 CMS
Genentech USA, Inc. $28.4403/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211591818 CMS
Amgen Inc. $17.0103/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228588411 CMS
GENZYME CORPORATION $92.5003/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233373526 CMS
Novartis Pharmaceuticals Corporation $53.0202/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200210790 CMS
AstraZeneca Pharmaceuticals LP $15.1202/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206191403 CMS
AstraZeneca Pharmaceuticals LP $13.6702/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206601286 CMS
AstraZeneca Pharmaceuticals LP $22.9402/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206876615 CMS
Amgen Inc. $7.8902/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227185909 CMS
AstraZeneca Pharmaceuticals LP $173.0402/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1207120880 CMS
AstraZeneca Pharmaceuticals LP $16.0701/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206292390 CMS
AstraZeneca Pharmaceuticals LP $24.3601/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1207138500 CMS
GENZYME CORPORATION $15.5301/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233373504 CMS
AstraZeneca Pharmaceuticals LP $13.7601/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206212913 CMS
AstraZeneca Pharmaceuticals LP $18.7301/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206376086 CMS
Amgen Inc. $5.0501/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227185905 CMS
GENZYME CORPORATION $21.5701/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233373500 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,765.37 73
PY2020 $664.90 43
PY2021 $1,196.00 57
PY2022 $1,493.23 59
PY2023 $2,979.29 56
PY2024 $3,226.54 70
PY2025 $2,126.47 75

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $3,950,529.31 645
PY2024 Recipient $43,825.25 17
PY2024 Principal investigator $2,746,480.16 466
PY2023 Recipient $535.01 1
PY2023 Principal investigator $2,561,960.55 951
PY2022 Principal investigator $1,562,855.45 131
PY2021 Principal investigator $254,191.94 34
PY2020 Principal investigator $106,758.78 18
PY2019 Recipient $54.90 1
PY2019 Principal investigator $89,894.48 40

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

645 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $600.00 12/31/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Ubrogepant for the Preventive Treatment of Menstrual Migraine with an Open-Label Extension No dispute reported 06/30/2026 1202535103
Principal investigator 1 ABBVIE INC. $1,440.00 12/31/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Single-attack Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202535105
Principal investigator 1 PFIZER INC. $4,739.00 12/31/2025 Non-covered Recipient Entity
CR Services Acquisition US LLC dba Centricity Research
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228815950
Principal investigator 1 PFIZER INC. $37,458.55 12/31/2025 Non-covered Recipient Entity
CR Services Acquisition US LLC dba Centricity Research
A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST VARICELLA ZOSTER VIRUS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228816234
Principal investigator 1 PFIZER INC. $128,335.80 12/31/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1228816333
Principal investigator 1 ABBVIE INC. $110.40 12/23/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202531716
Principal investigator 1 PFIZER INC. $21,325.50 12/23/2025 Non-covered Recipient Entity
CR Services Acquisition US LLC dba Centricity Research
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228815867
Principal investigator 1 Novo Nordisk AS $2,540.00 12/22/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH COLUMBUS
NN9536-4512 No dispute reported 06/30/2026 1213720654
Principal investigator 1 Novo Nordisk AS $6,702.80 12/22/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH
NN9536-7752 No dispute reported 06/30/2026 1213809715
Principal investigator 1 ModernaTX, Inc. $702.72 12/19/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978790
Principal investigator 1 ModernaTX, Inc. $4,095.96 12/19/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978838
Principal investigator 1 ModernaTX, Inc. $12,730.32 12/19/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978866
Principal investigator 1 ModernaTX, Inc. $850.30 12/19/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978888
Principal investigator 1 ModernaTX, Inc. $100.00 12/19/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252978926
Principal investigator 1 Boehringer Ingelheim International GmbH $119.88 12/17/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220771009
Principal investigator 1 Boehringer Ingelheim International GmbH $803.00 12/17/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220771011
Principal investigator 1 Boehringer Ingelheim International GmbH $38.28 12/17/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220771013
Principal investigator 1 PFIZER INC. $25,879.75 12/17/2025 Non-covered Recipient Entity
CR Services Acquisition US LLC dba Centricity Research
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228816663
Principal investigator 1 Madrigal Pharmaceuticals $97.50 12/16/2025 Non-covered Recipient Entity
AVENTIV RESEARCH INC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248254171
Principal investigator 1 Madrigal Pharmaceuticals $1,176.50 12/16/2025 Non-covered Recipient Entity
AVENTIV RESEARCH INC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248254174
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,056.00 12/15/2025 Non-covered Recipient Entity
Centricity Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220812218
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $236.25 12/15/2025 Non-covered Recipient Entity
Centricity Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220812220
Principal investigator 1 ModernaTX, Inc. $195.00 12/15/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978812
Principal investigator 1 Madrigal Pharmaceuticals $1,222.00 12/10/2025 Non-covered Recipient Entity
AVENTIV RESEARCH INC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248253798
Principal investigator 1 ABBVIE INC. $814.00 12/08/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202529616
Principal investigator 1 ABBVIE INC. $9,166.12 12/04/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202526790
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770995
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770997
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770999
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220771001
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220771003
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220771005
Principal investigator 1 Boehringer Ingelheim International GmbH $15.39 12/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220771007
Principal investigator 1 Madrigal Pharmaceuticals $26.00 11/27/2025 Non-covered Recipient Entity
AVENTIV RESEARCH INC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248253134
Principal investigator 1 Madrigal Pharmaceuticals $97.50 11/27/2025 Non-covered Recipient Entity
AVENTIV RESEARCH INC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248253150
Principal investigator 1 Madrigal Pharmaceuticals $97.50 11/27/2025 Non-covered Recipient Entity
AVENTIV RESEARCH INC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248253155
Principal investigator 1 Madrigal Pharmaceuticals $292.50 11/27/2025 Non-covered Recipient Entity
AVENTIV RESEARCH INC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248253159
Principal investigator 1 Madrigal Pharmaceuticals $52.00 11/27/2025 Non-covered Recipient Entity
AVENTIV RESEARCH INC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248253163
Principal investigator 1 Madrigal Pharmaceuticals $1,222.00 11/27/2025 Non-covered Recipient Entity
AVENTIV RESEARCH INC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248253172
Principal investigator 1 Madrigal Pharmaceuticals $195.00 11/27/2025 Non-covered Recipient Entity
AVENTIV RESEARCH INC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248253176
Principal investigator 1 Madrigal Pharmaceuticals $400.00 11/27/2025 Non-covered Recipient Entity
AVENTIV RESEARCH INC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248253180
Principal investigator 1 Madrigal Pharmaceuticals $26.00 11/27/2025 Non-covered Recipient Entity
AVENTIV RESEARCH INC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248253184
Principal investigator 1 Madrigal Pharmaceuticals $97.50 11/27/2025 Non-covered Recipient Entity
AVENTIV RESEARCH INC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248253192
Principal investigator 1 ModernaTX, Inc. $1,440.00 11/27/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978770
Principal investigator 1 ModernaTX, Inc. $850.30 11/27/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978788
Principal investigator 1 ModernaTX, Inc. $1,000.00 11/27/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978802
Principal investigator 1 ModernaTX, Inc. $8,486.88 11/27/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978810
Principal investigator 1 ModernaTX, Inc. $8,432.64 11/27/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978826
Principal investigator 1 ModernaTX, Inc. $3,981.12 11/27/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978896
Principal investigator 1 PFIZER INC. $5,923.75 11/27/2025 Non-covered Recipient Entity
CR Services Acquisition US LLC dba Centricity Research
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228812795
Principal investigator 1 PFIZER INC. $1,000.00 11/26/2025 Non-covered Recipient Entity
CR Services Acquisition US LLC dba Centricity Research
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228812749
Principal investigator 1 PFIZER INC. $13,074.92 11/26/2025 Non-covered Recipient Entity
CR Services Acquisition US LLC dba Centricity Research
A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE No dispute reported 06/30/2026 1228812760
Principal investigator 1 ModernaTX, Inc. $2,785.90 11/21/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252978910
Principal investigator 1 ABBVIE INC. $600.00 11/20/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202524846
Principal investigator 1 Novo Nordisk AS $1,800.00 11/20/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH
NN9536-7752 No dispute reported 06/30/2026 1213815443
Principal investigator 1 PFIZER INC. $44.00 11/19/2025 Non-covered Recipient Entity
CR Services Acquisition US LLC dba Centricity Research
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228812754
Principal investigator 1 PFIZER INC. $10,662.75 11/15/2025 Non-covered Recipient Entity
CR Services Acquisition US LLC dba Centricity Research
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228813488
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $3,159.80 11/14/2025 Non-covered Recipient Entity
CR Services Acquisition US LLC d/b/a Centricity Research
A PHASE I, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND BIOMARKERS OF DONQ52 IN CELIAC DISEASE PATIENTS No dispute reported 06/30/2026 1211591305
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $1,289.00 11/14/2025 Non-covered Recipient Entity
CR Services Acquisition US LLC d/b/a Centricity Research
A PHASE I, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND BIOMARKERS OF DONQ52 IN CELIAC DISEASE PATIENTS No dispute reported 06/30/2026 1211591317
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $108.00 11/14/2025 Non-covered Recipient Entity
CR Services Acquisition US LLC d/b/a Centricity Research
A PHASE I, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND BIOMARKERS OF DONQ52 IN CELIAC DISEASE PATIENTS No dispute reported 06/30/2026 1211591322
Principal investigator 1 PFIZER INC. $2,369.50 11/11/2025 Non-covered Recipient Entity
CR Services Acquisition US LLC dba Centricity Research
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228812807
Principal investigator 1 ABBVIE INC. $1,100.00 11/06/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202523323
Principal investigator 1 ABBVIE INC. $165.60 11/06/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202523345
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.00 11/06/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220815127
Principal investigator 1 ABBVIE INC. $8,523.48 11/05/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202522159
Principal investigator 1 ModernaTX, Inc. $390.00 11/05/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978798
Principal investigator 1 Eli Lilly and Company $3,528.07 11/03/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1187879367
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770983
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770985
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770987
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770989
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770991
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770993
Principal investigator 1 PFIZER INC. $2,568.16 11/01/2025 Non-covered Recipient Entity
CR Services Acquisition US LLC dba Centricity Research
A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE No dispute reported 06/30/2026 1228812801
Principal investigator 1 ABBVIE INC. $55.20 10/30/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202519765
Principal investigator 1 ABBVIE INC. $55.20 10/30/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202519807
Principal investigator 1 ABBVIE INC. $165.60 10/30/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202519845
Principal investigator 1 ABBVIE INC. $110.40 10/30/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202519877
Principal investigator 1 ABBVIE INC. $55.20 10/29/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202519547
Principal investigator 1 ABBVIE INC. $1,100.00 10/29/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202519549
Principal investigator 1 ABBVIE INC. $281.52 10/29/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202519589
Principal investigator 1 ABBVIE INC. $255.20 10/29/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202519591
Principal investigator 1 ABBVIE INC. $600.00 10/29/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202519593
Principal investigator 1 ABBVIE INC. $800.00 10/29/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202519595
Principal investigator 1 ABBVIE INC. $55.20 10/29/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202519607
Principal investigator 1 ABBVIE INC. $55.20 10/29/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202519625
Principal investigator 1 ABBVIE INC. $165.60 10/29/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202519627
Principal investigator 1 ABBVIE INC. $55.20 10/29/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202519629
Principal investigator 1 ABBVIE INC. $55.20 10/29/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202519631
Principal investigator 1 ABBVIE INC. $55.20 10/29/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202519635
Principal investigator 1 ModernaTX, Inc. $700.00 10/29/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252978906
Principal investigator 1 ModernaTX, Inc. $300.00 10/29/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252978950
Principal investigator 1 Novo Nordisk AS $700.00 10/29/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH COLUMBUS
NN9536-4512 No dispute reported 06/30/2026 1213731164
Principal investigator 1 Novo Nordisk AS $1,500.00 10/29/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH
NN9536-7752 No dispute reported 06/30/2026 1213733201
Principal investigator 1 Novo Nordisk AS $375.00 10/29/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH
NN9536-7752 No dispute reported 06/30/2026 1213736902
Principal investigator 1 Novo Nordisk AS $465.62 10/29/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH COLUMBUS
NN9536-4512 No dispute reported 06/30/2026 1213738290
Principal investigator 1 Novo Nordisk AS $800.00 10/29/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH
NN9536-7752 No dispute reported 06/30/2026 1213754443
Principal investigator 1 Novo Nordisk AS $1,500.00 10/29/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH COLUMBUS
NN9536-4512 No dispute reported 06/30/2026 1213763447
Principal investigator 1 Novo Nordisk AS $825.00 10/29/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH COLUMBUS
NN9536-4512 No dispute reported 06/30/2026 1213764481
Principal investigator 1 Novo Nordisk AS $700.00 10/29/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH
NN9536-7752 No dispute reported 06/30/2026 1213777489
Principal investigator 1 Novo Nordisk AS $5,080.40 10/29/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH
NN9536-7752 No dispute reported 06/30/2026 1213806279
Principal investigator 1 Novo Nordisk AS $2,900.00 10/29/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH COLUMBUS
NN9536-4512 No dispute reported 06/30/2026 1213816366
Principal investigator 1 Novo Nordisk AS $582.00 10/29/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH COLUMBUS
NN9536-4512 No dispute reported 06/30/2026 1213822600
Principal investigator 1 Novo Nordisk AS $1,000.00 10/29/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH
NN9536-7752 No dispute reported 06/30/2026 1213838594
Principal investigator 1 Novo Nordisk AS $150.00 10/29/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH
NN9536-7752 No dispute reported 06/30/2026 1213847851
Principal investigator 1 Novo Nordisk AS $7,215.00 10/29/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH COLUMBUS
NN9536-4512 No dispute reported 06/30/2026 1213850389
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $195.67 10/28/2025 Non-covered Recipient Entity
Centricity Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220812216
Principal investigator 1 ModernaTX, Inc. $6,324.48 10/27/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978854
Principal investigator 1 ModernaTX, Inc. $4,344.78 10/27/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978856
Principal investigator 1 ModernaTX, Inc. $400.00 10/24/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252978964
Principal investigator 1 ABBVIE INC. $108.00 10/23/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202518423
Principal investigator 1 ABBVIE INC. $56.00 10/23/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202518425
Principal investigator 1 SANOFI PASTEUR INC. $844.80 10/23/2025 Non-covered Recipient Entity
Cr Services Acquisition Us Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1226088325
Principal investigator 1 SANOFI PASTEUR INC. $13,400.00 10/23/2025 Non-covered Recipient Entity
Cr Services Acquisition Us Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1226088331
Principal investigator 1 SANOFI PASTEUR INC. $1,175.00 10/23/2025 Non-covered Recipient Entity
Cr Services Acquisition Us Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1226088336
Principal investigator 1 ModernaTX, Inc. $9,994.40 10/22/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252978954
Principal investigator 1 ModernaTX, Inc. $130.00 10/17/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252978912
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $108.00 10/16/2025 Non-covered Recipient Entity
CR Services Acquisition US LLC d/b/a Centricity Research
A PHASE I, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND BIOMARKERS OF DONQ52 IN CELIAC DISEASE PATIENTS No dispute reported 06/30/2026 1211591309
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $800.00 10/16/2025 Non-covered Recipient Entity
CR Services Acquisition US LLC d/b/a Centricity Research
A PHASE I, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND BIOMARKERS OF DONQ52 IN CELIAC DISEASE PATIENTS No dispute reported 06/30/2026 1211591312
Principal investigator 1 ModernaTX, Inc. $487.50 10/16/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978780
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,320.00 10/15/2025 Non-covered Recipient Entity
Centricity Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220812214
Principal investigator 1 PFIZER INC. $47,390.00 10/11/2025 Non-covered Recipient Entity
CR Services Acquisition US LLC dba Centricity Research
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228817994
Principal investigator 1 ModernaTX, Inc. $756.00 10/10/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978786
Principal investigator 1 ABBVIE INC. $4,782.99 10/09/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202513851
Principal investigator 1 ABBVIE INC. $200.00 10/09/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202515291
Principal investigator 1 ABBVIE INC. $1,214.50 10/09/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202515761
Principal investigator 1 ABBVIE INC. $56.00 10/09/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202516155
Principal investigator 1 ABBVIE INC. $147.18 10/09/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202516283
Principal investigator 1 ABBVIE INC. $200.00 10/09/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202516293
Principal investigator 1 ABBVIE INC. $2,939.10 10/09/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202516319
Principal investigator 1 ABBVIE INC. $500.00 10/09/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202516425
Principal investigator 1 ABBVIE INC. $54.00 10/09/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202516427
Principal investigator 1 Eli Lilly and Company $244.68 10/08/2025 Non-covered Recipient Entity
COLUMBUS CLINICAL RESEARCH INC
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1187880343
Principal investigator 1 PFIZER INC. $1,143.80 10/08/2025 Non-covered Recipient Entity
CR Services Acquisition US LLC dba Centricity Research
A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE No dispute reported 06/30/2026 1228716353
Principal investigator 1 ABBVIE INC. $200.00 10/07/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202513477
Principal investigator 1 Madrigal Pharmaceuticals $1,222.00 10/07/2025 Non-covered Recipient Entity
AVENTIV RESEARCH INC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248251364
Principal investigator 1 AstraZeneca Pharmaceuticals LP $147,192.32 10/02/2025 Non-covered Recipient Entity
CR SERVICES ACQUSITION US, LLC
A Phase III Randomised Double Blind PlaceboControlled Parallel Group Study to Assess the Effect of AZD0780 on Low Density Lipoprotein Cholesterol in Patients With Elevated Low Density Lipoprotein Cholesterol and Clinical Atherosclerotic Cardiovascular Disease or at Risk for a First Atherosclerotic Cardiovascular Disease Event No dispute reported 06/30/2026 1185547259
Principal investigator 1 Boehringer Ingelheim International GmbH $30.79 10/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770969
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 10/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770971
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770973
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770975
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770977
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770979
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770981
Principal investigator 1 ModernaTX, Inc. $100.00 10/01/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252978958
Principal investigator 1 ModernaTX, Inc. $4,038.54 09/29/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978808
Principal investigator 1 ModernaTX, Inc. $4,919.04 09/29/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978816
Principal investigator 1 PFIZER INC. $100.00 09/27/2025 Non-covered Recipient Entity
CR Services Acquisition US LLC dba Centricity Research
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228836007
Principal investigator 1 PFIZER INC. $28,270.55 09/24/2025 Non-covered Recipient Entity
CR Services Acquisition US LLC dba Centricity Research
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228836147
Principal investigator 1 Novo Nordisk AS $72.10 09/19/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH COLUMBUS
NN9536-4512 No dispute reported 06/30/2026 1213770407
Principal investigator 1 Novo Nordisk AS $3,257.80 09/19/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH
NN9536-7752 No dispute reported 06/30/2026 1213775069
Principal investigator 1 Novo Nordisk AS $3,705.00 09/19/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH COLUMBUS
NN9536-4512 No dispute reported 06/30/2026 1213780182
Principal investigator 1 Novo Nordisk AS $75.00 09/19/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH COLUMBUS
NN9536-4512 No dispute reported 06/30/2026 1213803242
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $42,645.00 09/18/2025 Non-covered Recipient Entity
Centricity Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220812212
Principal investigator 1 ModernaTX, Inc. $3,511.30 09/17/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252978960
Principal investigator 1 ABBVIE INC. $55.20 09/11/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202510758
Principal investigator 1 ABBVIE INC. $165.60 09/11/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202510760
Principal investigator 1 PFIZER INC. $8,293.25 09/09/2025 Non-covered Recipient Entity
CR Services Acquisition US LLC dba Centricity Research
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228836081
Principal investigator 1 PFIZER INC. $79,220.00 09/09/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1228836086
Principal investigator 1 Boehringer Ingelheim International GmbH $150.00 09/08/2025 Non-covered Recipient Entity
Centricity Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220726055
Principal investigator 1 Madrigal Pharmaceuticals $2,065.05 09/05/2025 Non-covered Recipient Entity
AVENTIV RESEARCH INC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248249815
Principal investigator 1 ABBVIE INC. $25,023.96 09/04/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202508582
Principal investigator 1 ABBVIE INC. $1,134.00 09/04/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202509762
Principal investigator 1 ABBVIE INC. $3,879.40 09/04/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202509764
Principal investigator 1 ModernaTX, Inc. $65.00 09/03/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978800
Principal investigator 1 ModernaTX, Inc. $78.00 09/03/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978832
Principal investigator 1 PFIZER INC. $7,750.93 09/03/2025 Non-covered Recipient Entity
CR Services Acquisition US LLC dba Centricity Research
A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE No dispute reported 06/30/2026 1228836001
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770825
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770827
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770829
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770831
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770833
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 09/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770967
Principal investigator 1 ModernaTX, Inc. $1,700.60 08/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978768
Principal investigator 1 ModernaTX, Inc. $1,405.44 08/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978772
Principal investigator 1 ModernaTX, Inc. $4,651.02 08/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978824
Principal investigator 1 ModernaTX, Inc. $28,963.22 08/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978874
Principal investigator 1 ModernaTX, Inc. $83.20 08/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007525
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 08/26/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770889
Principal investigator 1 Boehringer Ingelheim International GmbH $8.70 08/26/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770891
Principal investigator 1 ABBVIE INC. $55.20 08/25/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202505689
Principal investigator 1 ABBVIE INC. $350.52 08/25/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202505691
Principal investigator 1 ABBVIE INC. $110.40 08/25/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202505697
Principal investigator 1 AstraZeneca Pharmaceuticals LP $22,832.43 08/22/2025 Non-covered Recipient Entity
CR SERVICES ACQUSITION US, LLC
a phase III,randomised,double blind,placebo controlled,event driven study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on renal outcomes and cardiovascular mortality in participants with chronic kidney disease and high blood pressure No dispute reported 06/30/2026 1185547257
Principal investigator 1 Novo Nordisk AS $21,258.90 08/22/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH
NN9536-7752 No dispute reported 06/30/2026 1213777406
Principal investigator 1 PFIZER INC. $2,369.50 08/21/2025 Non-covered Recipient Entity
CR Services Acquisition US LLC dba Centricity Research
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228843447
Principal investigator 1 ModernaTX, Inc. $4,512.30 08/20/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252978920
Principal investigator 1 Boehringer Ingelheim International GmbH $150.00 08/11/2025 Non-covered Recipient Entity
Centricity Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220726049
Principal investigator 1 ABBVIE INC. $17,844.60 08/06/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202503031
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,336.00 08/06/2025 Non-covered Recipient Entity
Centricity Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220812210
Principal investigator 1 PFIZER INC. $44,481.89 08/05/2025 Non-covered Recipient Entity
CR Services Acquisition US LLC dba Centricity Research
A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE No dispute reported 06/30/2026 1228843683
Principal investigator 1 PFIZER INC. $2,429.50 08/05/2025 Non-covered Recipient Entity
CR Services Acquisition US LLC dba Centricity Research
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228843758
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770823
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770847
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770849
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770851
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770853
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770855
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770857
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770859
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770861
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770863
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770865
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 08/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770965
Principal investigator 1 PFIZER INC. $47,930.00 08/01/2025 Non-covered Recipient Entity
CR Services Acquisition US LLC dba Centricity Research
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228843423
Principal investigator 1 AstraZeneca Pharmaceuticals LP $190,279.80 07/31/2025 Non-covered Recipient Entity
CR SERVICES ACQUSITION US, LLC
A Phase IIb Randomised, Double-blind, Placebocontrolled Study to Evaluate the Efficacy, Safety and Tolerability of Coadministration of AZD9550 and AZD6234 in Participants Living With Obesity or Overweight with Co-morbidity (ASCEND) No dispute reported 06/30/2026 1185547261
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 07/28/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770885
Principal investigator 1 Boehringer Ingelheim International GmbH $1.74 07/28/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770887
Principal investigator 1 Eli Lilly and Company $131.00 07/28/2025 Non-covered Recipient Entity
COLUMBUS CLINICAL RESEARCH INC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1187878801
Principal investigator 1 ModernaTX, Inc. $2,108.16 07/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978836
Principal investigator 1 ModernaTX, Inc. $1,148.40 07/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978848
Principal investigator 1 PFIZER INC. $4,370.00 07/26/2025 Non-covered Recipient Entity
CR Services Acquisition US LLC dba Centricity Research
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228846858
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $11,819.50 07/18/2025 Non-covered Recipient Entity
Aventiv Research, Inc.
A PHASE I, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND BIOMARKERS OF DONQ52 IN CELIAC DISEASE PATIENTS No dispute reported 06/30/2026 1211576480
Principal investigator 1 ModernaTX, Inc. $3,363.10 07/18/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252978940
Principal investigator 1 PFIZER INC. $47,422.55 07/17/2025 Non-covered Recipient Entity
CR Services Acquisition US LLC dba Centricity Research
A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE No dispute reported 06/30/2026 1228846850
Principal investigator 1 Novo Nordisk AS $700.00 07/16/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH COLUMBUS
NN9536-4512 No dispute reported 06/30/2026 1213722267
Principal investigator 1 Novo Nordisk AS $4,400.00 07/16/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH COLUMBUS
NN9536-4512 No dispute reported 06/30/2026 1213799364
Principal investigator 1 Novo Nordisk AS $57.72 07/16/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH
NN9536-7752 No dispute reported 06/30/2026 1213805843
Principal investigator 1 Novartis Pharmaceuticals Corporation $14,700.78 07/15/2025 Non-covered Recipient Entity
CARE SERVICES ACQUISITION US
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista No dispute reported 06/30/2026 1190309848
Principal investigator 1 ModernaTX, Inc. $951.60 07/14/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978834
Principal investigator 1 PFIZER INC. $18,956.00 07/11/2025 Non-covered Recipient Entity
CR Services Acquisition US LLC dba Centricity Research
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228846843
Principal investigator 1 PFIZER INC. $91,274.90 07/08/2025 Non-covered Recipient Entity
CR Services Acquisition US LLC dba Centricity Research
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228846895
Principal investigator 1 ABBVIE INC. $6,131.68 07/02/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202495597
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 07/01/2025 Non-covered Recipient Entity
Centricity Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220726047
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770837
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770839
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770841
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770843
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770845
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 07/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770963
Principal investigator 1 PFIZER INC. $2,188.00 07/01/2025 Non-covered Recipient Entity
CR Services Acquisition US LLC dba Centricity Research
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228846803
Principal investigator 1 ModernaTX, Inc. $40.30 06/30/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007483
Principal investigator 1 ModernaTX, Inc. $3,674.88 06/27/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978764
Principal investigator 1 ModernaTX, Inc. $20,051.46 06/27/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978796
Principal investigator 1 ModernaTX, Inc. $7,729.92 06/27/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978804
Principal investigator 1 PFIZER INC. $5,503.96 06/27/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1228852090
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $7,778.00 06/26/2025 Non-covered Recipient Entity
Centricity Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220812208
Principal investigator 1 PFIZER INC. $154,723.10 06/26/2025 Non-covered Recipient Entity
CR Services Acquisition US LLC dba Centricity Research
A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE No dispute reported 06/30/2026 1228851115
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $66.00 06/24/2025 Non-covered Recipient Entity
Centricity Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220812206
Principal investigator 1 Eli Lilly and Company $6,435.00 06/23/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A STUDY OF LY3819469 IN PARTICIPANTS WITH ELEVATED LIPOPROTEIN(A) [LP(A)] No dispute reported 06/30/2026 1187880976
Principal investigator 1 ModernaTX, Inc. $14,405.76 06/18/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978776
Principal investigator 1 ModernaTX, Inc. $3,847.14 06/18/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978814
Principal investigator 1 ModernaTX, Inc. $15,595.58 06/18/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978902
Principal investigator 1 ModernaTX, Inc. $8,502.00 06/18/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252978956
Principal investigator 1 ModernaTX, Inc. $5,796.70 06/18/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007529
Principal investigator 1 ABBVIE INC. $55.20 06/17/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202491773
Principal investigator 1 PFIZER INC. $2,751.98 06/14/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1228851109
Principal investigator 1 ModernaTX, Inc. $100.00 06/13/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252978936
Principal investigator 1 PFIZER INC. $89,513.10 06/10/2025 Non-covered Recipient Entity
CR Services Acquisition US LLC dba Centricity Research
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228852083
Principal investigator 1 ABBVIE INC. $179.00 06/05/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202490409
Principal investigator 1 ABBVIE INC. $19,029.50 06/03/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202488331
Principal investigator 1 ABBVIE INC. $413.00 06/03/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202488333
Principal investigator 1 ModernaTX, Inc. $50.00 06/02/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252978904
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 06/01/2025 Non-covered Recipient Entity
Centricity Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220726053
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770835
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770917
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770919
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770921
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770923
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 06/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770961
Principal investigator 1 PFIZER INC. $18,500.00 05/30/2025 Non-covered Recipient Entity
CR Services Acquisition US LLC dba Centricity Research
A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE No dispute reported 06/30/2026 1228855668
Principal investigator 1 PFIZER INC. $7,882.14 05/30/2025 Non-covered Recipient Entity
CR Services Acquisition US LLC dba Centricity Research
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228858403
Principal investigator 1 ABBVIE INC. $55.20 05/29/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202486897
Principal investigator 1 ABBVIE INC. $110.40 05/29/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202486907
Principal investigator 1 ABBVIE INC. $110.40 05/29/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202486909
Principal investigator 1 ABBVIE INC. $55.20 05/29/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202486911
Principal investigator 1 ABBVIE INC. $55.20 05/29/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202486913
Principal investigator 1 ABBVIE INC. $1,024.20 05/29/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202486931
Principal investigator 1 ABBVIE INC. $4,375.00 05/29/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202486933
Principal investigator 1 ABBVIE INC. $332.40 05/29/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202487053
Principal investigator 1 ABBVIE INC. $600.00 05/29/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202487055
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 05/29/2025 Non-covered Recipient Entity
Centricity Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220726043
Principal investigator 1 ABBVIE INC. $55.20 05/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202486441
Principal investigator 1 ABBVIE INC. $110.40 05/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202486459
Principal investigator 1 ABBVIE INC. $55.20 05/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202486461
Principal investigator 1 ABBVIE INC. $55.20 05/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202486463
Principal investigator 1 ABBVIE INC. $110.40 05/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202486465
Principal investigator 1 ABBVIE INC. $55.20 05/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202486467
Principal investigator 1 ABBVIE INC. $165.60 05/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202486475
Principal investigator 1 ABBVIE INC. $600.00 05/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202486477
Principal investigator 1 ABBVIE INC. $55.20 05/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202486485
Principal investigator 1 ABBVIE INC. $110.40 05/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202486487
Principal investigator 1 ABBVIE INC. $55.20 05/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202486515
Principal investigator 1 ABBVIE INC. $55.20 05/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202486517
Principal investigator 1 ABBVIE INC. $600.00 05/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202486519
Principal investigator 1 ABBVIE INC. $55.20 05/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202486521
Principal investigator 1 ABBVIE INC. $55.20 05/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202486525
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 05/28/2025 Non-covered Recipient Entity
Centricity Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220726019
Principal investigator 1 ModernaTX, Inc. $1,700.60 05/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978766
Principal investigator 1 ModernaTX, Inc. $11,292.60 05/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978784
Principal investigator 1 ModernaTX, Inc. $3,341.91 05/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978872
Principal investigator 1 ModernaTX, Inc. $46,730.88 05/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978876
Principal investigator 1 ModernaTX, Inc. $28,577.90 05/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978894
Principal investigator 1 ModernaTX, Inc. $12,854.40 05/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007491
Principal investigator 1 ModernaTX, Inc. $55,291.60 05/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007493
Principal investigator 1 ModernaTX, Inc. $9,079.20 05/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007523
Principal investigator 1 PFIZER INC. $3,789.22 05/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1228858362
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 05/27/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770881
Principal investigator 1 Boehringer Ingelheim International GmbH $1.74 05/27/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770883
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $66.00 05/27/2025 Non-covered Recipient Entity
Centricity Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220812204
Principal investigator 1 PFIZER INC. $1,089.15 05/27/2025 Non-covered Recipient Entity
Centricity Research Columbus Ohio Multispecialty
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228707281
Principal investigator 1 PFIZER INC. $1,089.15 05/27/2025 Non-covered Recipient Entity
Centricity Research Columbus Ohio Multispecialty
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228840701
Principal investigator 1 Boehringer Ingelheim International GmbH $200.00 05/26/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726255
Principal investigator 1 ModernaTX, Inc. $650.00 05/23/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978898
Principal investigator 1 Novo Nordisk AS $44.88 05/23/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH COLUMBUS
NN9536-4512 No dispute reported 06/30/2026 1213829413
Principal investigator 1 Novo Nordisk AS $616.00 05/23/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH COLUMBUS
NN9536-4512 No dispute reported 06/30/2026 1213847951
Principal investigator 1 Novo Nordisk AS $300.00 05/21/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH
NN9536-7752 No dispute reported 06/30/2026 1213798483
Principal investigator 1 Novo Nordisk AS $4,855.50 05/21/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH
NN9536-7752 No dispute reported 06/30/2026 1213818083
Principal investigator 1 PFIZER INC. $18.98 05/21/2025 Non-covered Recipient Entity
Centricity Research Columbus Ohio Multispecialty
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228707279
Principal investigator 1 PFIZER INC. $72.61 05/21/2025 Non-covered Recipient Entity
Centricity Research Columbus Ohio Multispecialty
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228707455
Principal investigator 1 PFIZER INC. $18.98 05/21/2025 Non-covered Recipient Entity
Centricity Research Columbus Ohio Multispecialty
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228840680
Principal investigator 1 PFIZER INC. $72.61 05/21/2025 Non-covered Recipient Entity
Centricity Research Columbus Ohio Multispecialty
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228840693
Principal investigator 1 PFIZER INC. $9,913.46 05/19/2025 Non-covered Recipient Entity
Centricity Research Columbus
A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE No dispute reported 06/30/2026 1228707101
Principal investigator 1 PFIZER INC. $9,913.46 05/19/2025 Non-covered Recipient Entity
Centricity Research Columbus Ohio Multispecialty
A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE No dispute reported 06/30/2026 1228842725
Principal investigator 1 SANOFI PASTEUR INC. $400.00 05/19/2025 Non-covered Recipient Entity
Cr Services Acquisition Us Llc
A Phase 3, Randomized, Modified Double-blind, 2-arm Study to Evaluate the Immunogenicity and Safety of High-Dose Inactivated Influenza Vaccine (IIV-HD) Compared With a Standard-dose Inactivated Influenza Vaccine (IIV-SD) in Participants 50 Through 64 Years of Age. No dispute reported 06/30/2026 1226088297
Principal investigator 1 Madrigal Pharmaceuticals $292.50 05/16/2025 Non-covered Recipient Entity
AVENTIV RESEARCH INC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248244003
Principal investigator 1 Madrigal Pharmaceuticals $1,300.00 05/16/2025 Non-covered Recipient Entity
AVENTIV RESEARCH INC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248244006
Principal investigator 1 ModernaTX, Inc. $6,576.70 05/16/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252978922
Principal investigator 1 Madrigal Pharmaceuticals $52.00 05/15/2025 Non-covered Recipient Entity
AVENTIV RESEARCH INC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248243513
Principal investigator 1 Madrigal Pharmaceuticals $292.50 05/15/2025 Non-covered Recipient Entity
AVENTIV RESEARCH INC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248243525
Principal investigator 1 Madrigal Pharmaceuticals $1,222.00 05/15/2025 Non-covered Recipient Entity
AVENTIV RESEARCH INC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248243538
Principal investigator 1 Madrigal Pharmaceuticals $97.50 05/15/2025 Non-covered Recipient Entity
AVENTIV RESEARCH INC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248243550
Principal investigator 1 Madrigal Pharmaceuticals $26.00 05/15/2025 Non-covered Recipient Entity
AVENTIV RESEARCH INC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248243554
Principal investigator 1 Madrigal Pharmaceuticals $195.00 05/15/2025 Non-covered Recipient Entity
AVENTIV RESEARCH INC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248243558
Principal investigator 1 Madrigal Pharmaceuticals $65.00 05/15/2025 Non-covered Recipient Entity
AVENTIV RESEARCH INC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248243561
Principal investigator 1 Madrigal Pharmaceuticals $97.50 05/15/2025 Non-covered Recipient Entity
AVENTIV RESEARCH INC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248243565
Principal investigator 1 Madrigal Pharmaceuticals $26.00 05/15/2025 Non-covered Recipient Entity
AVENTIV RESEARCH INC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248243569
Principal investigator 1 Madrigal Pharmaceuticals $1,222.00 05/15/2025 Non-covered Recipient Entity
AVENTIV RESEARCH INC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248243574
Principal investigator 1 Madrigal Pharmaceuticals $65.00 05/15/2025 Non-covered Recipient Entity
AVENTIV RESEARCH INC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248243580
Principal investigator 1 Madrigal Pharmaceuticals $97.50 05/15/2025 Non-covered Recipient Entity
AVENTIV RESEARCH INC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248243587
Principal investigator 1 Madrigal Pharmaceuticals $97.50 05/15/2025 Non-covered Recipient Entity
AVENTIV RESEARCH INC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248243591
Principal investigator 1 Madrigal Pharmaceuticals $65.00 05/15/2025 Non-covered Recipient Entity
AVENTIV RESEARCH INC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248243600
Principal investigator 1 ModernaTX, Inc. $715.00 05/15/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007505
Principal investigator 1 PFIZER INC. $41,627.85 05/15/2025 Non-covered Recipient Entity
CR Services Acquisition US LLC dba Centricity Research
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228858355
Principal investigator 1 Madrigal Pharmaceuticals $338.00 05/14/2025 Non-covered Recipient Entity
AVENTIV RESEARCH INC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248243354
Principal investigator 1 Madrigal Pharmaceuticals $26.00 05/14/2025 Non-covered Recipient Entity
AVENTIV RESEARCH INC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248243357
Principal investigator 1 Madrigal Pharmaceuticals $1,248.00 05/14/2025 Non-covered Recipient Entity
AVENTIV RESEARCH INC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248243361
Principal investigator 1 Madrigal Pharmaceuticals $5,460.00 05/14/2025 Non-covered Recipient Entity
AVENTIV RESEARCH INC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248243366
Principal investigator 1 Madrigal Pharmaceuticals $97.50 05/14/2025 Non-covered Recipient Entity
AVENTIV RESEARCH INC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248243369
Principal investigator 1 Madrigal Pharmaceuticals $26.00 05/14/2025 Non-covered Recipient Entity
AVENTIV RESEARCH INC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248243373
Principal investigator 1 Madrigal Pharmaceuticals $487.50 05/14/2025 Non-covered Recipient Entity
AVENTIV RESEARCH INC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248243435
Principal investigator 1 Madrigal Pharmaceuticals $17,836.00 05/14/2025 Non-covered Recipient Entity
AVENTIV RESEARCH INC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248243439
Principal investigator 1 Madrigal Pharmaceuticals $12,376.00 05/14/2025 Non-covered Recipient Entity
AVENTIV RESEARCH INC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248243444
Principal investigator 1 Madrigal Pharmaceuticals $17,836.00 05/14/2025 Non-covered Recipient Entity
AVENTIV RESEARCH INC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248243448
Principal investigator 1 Madrigal Pharmaceuticals $52.00 05/14/2025 Non-covered Recipient Entity
AVENTIV RESEARCH INC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248243452
Principal investigator 1 Madrigal Pharmaceuticals $1,222.00 05/14/2025 Non-covered Recipient Entity
AVENTIV RESEARCH INC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248243456
Principal investigator 1 Madrigal Pharmaceuticals $26.00 05/14/2025 Non-covered Recipient Entity
AVENTIV RESEARCH INC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248243460
Principal investigator 1 Madrigal Pharmaceuticals $400.00 05/14/2025 Non-covered Recipient Entity
AVENTIV RESEARCH INC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248243465
Principal investigator 1 Madrigal Pharmaceuticals $1,248.00 05/14/2025 Non-covered Recipient Entity
AVENTIV RESEARCH INC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248243469
Principal investigator 1 Madrigal Pharmaceuticals $97.50 05/14/2025 Non-covered Recipient Entity
AVENTIV RESEARCH INC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248243473
Principal investigator 1 Madrigal Pharmaceuticals $975.00 05/14/2025 Non-covered Recipient Entity
AVENTIV RESEARCH INC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248243477
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,012.00 05/09/2025 Non-covered Recipient Entity
Centricity Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220812202
Principal investigator 1 PFIZER INC. $21,336.15 05/08/2025 Non-covered Recipient Entity
CR Services Acquisition US LLC dba Centricity Research
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228858399
Principal investigator 1 ABBVIE INC. $1,192.20 05/07/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202483079
Principal investigator 1 ABBVIE INC. $17,498.65 05/07/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202483157
Principal investigator 1 ABBVIE INC. $567.00 05/07/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202483923
Principal investigator 1 ModernaTX, Inc. $45.50 05/07/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978818
Principal investigator 1 ModernaTX, Inc. $71.50 05/07/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978858
Principal investigator 1 ModernaTX, Inc. $312.00 05/07/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978890
Principal investigator 1 ModernaTX, Inc. $1,658.80 05/02/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252978944
Principal investigator 1 ABBVIE INC. $200.00 05/01/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202480849
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 05/01/2025 Non-covered Recipient Entity
Centricity Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220726045
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770907
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770909
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770911
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770913
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770915
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 05/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770959
Principal investigator 1 PFIZER INC. $8,478.39 05/01/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1228858410
Principal investigator 1 ModernaTX, Inc. $4,118.40 04/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007489
Principal investigator 1 ModernaTX, Inc. $10,255.70 04/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007495
Principal investigator 1 ModernaTX, Inc. $7,566.00 04/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007497
Principal investigator 1 ModernaTX, Inc. $2,675.40 04/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007501
Principal investigator 1 ModernaTX, Inc. $3,026.40 04/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007507
Principal investigator 1 ModernaTX, Inc. $13,020.80 04/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007537
Principal investigator 1 Madrigal Pharmaceuticals $5,569.20 04/23/2025 Non-covered Recipient Entity
AVENTIV RESEARCH INC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248242535
Principal investigator 1 ModernaTX, Inc. $5,864.30 04/23/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252978908
Principal investigator 1 Novo Nordisk AS $1,197.00 04/21/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH COLUMBUS
NN9536-4512 No dispute reported 06/30/2026 1213737590
Principal investigator 1 Novo Nordisk AS $383.00 04/21/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH COLUMBUS
NN9536-4512 No dispute reported 06/30/2026 1213740153
Principal investigator 1 Novo Nordisk AS $4,898.40 04/21/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH
NN9536-7752 No dispute reported 06/30/2026 1213741304
Principal investigator 1 Novo Nordisk AS $205.94 04/21/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH COLUMBUS
NN9536-4512 No dispute reported 06/30/2026 1213794149
Principal investigator 1 ModernaTX, Inc. $827.84 04/16/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007519
Principal investigator 1 PFIZER INC. $7,576.01 04/16/2025 Non-covered Recipient Entity
CR Services Acquisition US LLC dba Centricity Research
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228858321
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,637.00 04/11/2025 Non-covered Recipient Entity
Centricity Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220812200
Principal investigator 1 PFIZER INC. $3,448.16 04/09/2025 Non-covered Recipient Entity
Centricity Research Columbus
A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE No dispute reported 06/30/2026 1228707277
Principal investigator 1 PFIZER INC. $3,448.16 04/09/2025 Non-covered Recipient Entity
Centricity Research Columbus Ohio Multispecialty
A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE No dispute reported 06/30/2026 1228842698
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $400.00 04/08/2025 Non-covered Recipient Entity
Aventiv Research, Inc.
A PHASE I, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND BIOMARKERS OF DONQ52 IN CELIAC DISEASE PATIENTS No dispute reported 06/30/2026 1211576477
Principal investigator 1 ABBVIE INC. $6,122.28 04/03/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202470996
Principal investigator 1 ModernaTX, Inc. $130.00 04/02/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252978930
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 04/01/2025 Non-covered Recipient Entity
Centricity Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220726041
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770897
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770899
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770901
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770903
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770905
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 04/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770957
Principal investigator 1 PFIZER INC. $12,930.60 03/31/2025 Non-covered Recipient Entity
Centricity Research Columbus
A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE No dispute reported 06/30/2026 1228707379
Principal investigator 1 PFIZER INC. $12,930.60 03/31/2025 Non-covered Recipient Entity
Centricity Research Columbus Ohio Multispecialty
A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE No dispute reported 06/30/2026 1228842705
Principal investigator 1 Novo Nordisk AS $681.00 03/28/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH COLUMBUS
NN9536-4512 No dispute reported 06/30/2026 1213731443
Principal investigator 1 Novo Nordisk AS $33,653.75 03/28/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH
NN9536-7752 No dispute reported 06/30/2026 1213741033
Principal investigator 1 Novo Nordisk AS $836.88 03/28/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH COLUMBUS
NN9536-4512 No dispute reported 06/30/2026 1213802857
Principal investigator 1 PFIZER INC. $55,097.40 03/28/2025 Non-covered Recipient Entity
CR Services Acquisition US LLC dba Centricity Research
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228861212
Principal investigator 1 Boehringer Ingelheim International GmbH $2,980.00 03/24/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726183
Principal investigator 1 Boehringer Ingelheim International GmbH $288.00 03/24/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726189
Principal investigator 1 Boehringer Ingelheim International GmbH $800.00 03/24/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726201
Principal investigator 1 Boehringer Ingelheim International GmbH $2,200.00 03/24/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726219
Principal investigator 1 ModernaTX, Inc. $1,054.08 03/24/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978762
Principal investigator 1 ModernaTX, Inc. $161.19 03/24/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978880
Principal investigator 1 ModernaTX, Inc. $121.53 03/24/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978882
Principal investigator 1 ModernaTX, Inc. $15,132.00 03/24/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007503
Principal investigator 1 ModernaTX, Inc. $1,337.70 03/24/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007515
Principal investigator 1 ModernaTX, Inc. $15,579.20 03/24/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007533
Principal investigator 1 PFIZER INC. $189.80 03/24/2025 Non-covered Recipient Entity
Centricity Research Columbus Ohio Multispecialty
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228707459
Principal investigator 1 PFIZER INC. $189.80 03/24/2025 Non-covered Recipient Entity
Centricity Research Columbus Ohio Multispecialty
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228840734
Principal investigator 1 PFIZER INC. $18,500.00 03/22/2025 Non-covered Recipient Entity
CR Services Acquisition US LLC dba Centricity Research
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228861220
Principal investigator 1 ModernaTX, Inc. $546.00 03/21/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252978916
Principal investigator 1 ModernaTX, Inc. $273.00 03/21/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252978918
Principal investigator 1 Boehringer Ingelheim International GmbH $90.00 03/19/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726167
Principal investigator 1 Boehringer Ingelheim International GmbH $3,150.00 03/19/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726169
Principal investigator 1 Boehringer Ingelheim International GmbH $112.00 03/19/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726175
Principal investigator 1 Boehringer Ingelheim International GmbH $12.43 03/19/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726177
Principal investigator 1 Boehringer Ingelheim International GmbH $90.00 03/19/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726179
Principal investigator 1 Boehringer Ingelheim International GmbH $17.86 03/19/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726191
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 03/19/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726195
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 03/19/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726199
Principal investigator 1 Boehringer Ingelheim International GmbH $12.48 03/19/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726205
Principal investigator 1 Boehringer Ingelheim International GmbH $18.25 03/19/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726213
Principal investigator 1 Boehringer Ingelheim International GmbH $12.48 03/19/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726215
Principal investigator 1 Boehringer Ingelheim International GmbH $3,150.00 03/19/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726221
Principal investigator 1 Boehringer Ingelheim International GmbH $17.76 03/19/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726229
Principal investigator 1 Boehringer Ingelheim International GmbH $3,150.00 03/19/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726231
Principal investigator 1 Boehringer Ingelheim International GmbH $90.00 03/19/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726239
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 03/19/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726243
Principal investigator 1 Boehringer Ingelheim International GmbH $90.00 03/19/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726247
Principal investigator 1 Boehringer Ingelheim International GmbH $30.29 03/19/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726253
Principal investigator 1 ModernaTX, Inc. $2,828.80 03/19/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252978928
Principal investigator 1 ModernaTX, Inc. $4,612.40 03/19/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252978934
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,445.00 03/17/2025 Non-covered Recipient Entity
Centricity Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220812198
Principal investigator 1 PFIZER INC. $1,279.80 03/17/2025 Non-covered Recipient Entity
Centricity Research Columbus Ohio Multispecialty
A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE No dispute reported 06/30/2026 1228716319
Principal investigator 1 PFIZER INC. $677.05 03/17/2025 Non-covered Recipient Entity
Centricity Research Columbus Ohio Multispecialty
A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE No dispute reported 06/30/2026 1228814736
Principal investigator 1 PFIZER INC. $793.65 03/17/2025 Non-covered Recipient Entity
Centricity Research Columbus Ohio Multispecialty
A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE No dispute reported 06/30/2026 1228814800
Principal investigator 1 SANOFI PASTEUR INC. $400.00 03/14/2025 Non-covered Recipient Entity
Cr Services Acquisition Us Llc
A Phase 3, Randomized, Modified Double-blind, 2-arm Study to Evaluate the Immunogenicity and Safety of High-Dose Inactivated Influenza Vaccine (IIV-HD) Compared With a Standard-dose Inactivated Influenza Vaccine (IIV-SD) in Participants 50 Through 64 Years of Age. No dispute reported 06/30/2026 1226088253
Principal investigator 1 ModernaTX, Inc. $504.00 03/12/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978852
Principal investigator 1 ModernaTX, Inc. $400.00 03/12/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978868
Principal investigator 1 ModernaTX, Inc. $390.00 03/12/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252978962
Principal investigator 1 PFIZER INC. $189.80 03/10/2025 Non-covered Recipient Entity
Centricity Research Columbus Ohio Multispecialty
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228707377
Principal investigator 1 PFIZER INC. $189.80 03/10/2025 Non-covered Recipient Entity
Centricity Research Columbus Ohio Multispecialty
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228840707
Principal investigator 1 PFIZER INC. $3,437.00 03/08/2025 Non-covered Recipient Entity
CR Services Acquisition US LLC dba Centricity Research
A PHASE 12 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA COVID19 VACCINE AND A RECOMBINANT INFLUENZA VACCINE ADMINISTERED AS A SINGLE INJECTION IN HEALTHY ADULTS 50 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1228861806
Principal investigator 1 ABBVIE INC. $21,752.57 03/07/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202461752
Principal investigator 1 ModernaTX, Inc. $3,311.36 03/07/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007487
Principal investigator 1 ModernaTX, Inc. $624.00 03/07/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007527
Principal investigator 1 ModernaTX, Inc. $91.00 03/06/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978794
Principal investigator 1 ModernaTX, Inc. $71.50 03/06/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978840
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 03/05/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726163
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 03/05/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726165
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 03/05/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726171
Principal investigator 1 Boehringer Ingelheim International GmbH $90.00 03/05/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726173
Principal investigator 1 Boehringer Ingelheim International GmbH $13.65 03/05/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726181
Principal investigator 1 Boehringer Ingelheim International GmbH $519.00 03/05/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726185
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 03/05/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726187
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 03/05/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726193
Principal investigator 1 Boehringer Ingelheim International GmbH $12.43 03/05/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726197
Principal investigator 1 Boehringer Ingelheim International GmbH $168.00 03/05/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726203
Principal investigator 1 Boehringer Ingelheim International GmbH $519.00 03/05/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726207
Principal investigator 1 Boehringer Ingelheim International GmbH $12.48 03/05/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726209
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 03/05/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726211
Principal investigator 1 Boehringer Ingelheim International GmbH $60.00 03/05/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726217
Principal investigator 1 Boehringer Ingelheim International GmbH $8.50 03/05/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726223
Principal investigator 1 Boehringer Ingelheim International GmbH $12.48 03/05/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726225
Principal investigator 1 Boehringer Ingelheim International GmbH $3,150.00 03/05/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726227
Principal investigator 1 Boehringer Ingelheim International GmbH $519.00 03/05/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726233
Principal investigator 1 Boehringer Ingelheim International GmbH $286.86 03/05/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726235
Principal investigator 1 Boehringer Ingelheim International GmbH $7.39 03/05/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726237
Principal investigator 1 Boehringer Ingelheim International GmbH $90.00 03/05/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726241
Principal investigator 1 Boehringer Ingelheim International GmbH $3,150.00 03/05/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726245
Principal investigator 1 Boehringer Ingelheim International GmbH $12.48 03/05/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726249
Principal investigator 1 Boehringer Ingelheim International GmbH $8.02 03/05/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726251
Principal investigator 1 ModernaTX, Inc. $943.80 03/05/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252978952
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 03/01/2025 Non-covered Recipient Entity
Centricity Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220726039
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770893
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770895
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770945
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770947
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770949
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 03/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770955
Principal investigator 1 Boehringer Ingelheim International GmbH $2.14 02/28/2025 Non-covered Recipient Entity
Centricity Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220726023
Principal investigator 1 Boehringer Ingelheim International GmbH $12.86 02/28/2025 Non-covered Recipient Entity
Centricity Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220726025
Principal investigator 1 Boehringer Ingelheim International GmbH $239.89 02/28/2025 Non-covered Recipient Entity
Centricity Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220726027
Principal investigator 1 Boehringer Ingelheim International GmbH $5.52 02/28/2025 Non-covered Recipient Entity
Centricity Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220726029
Principal investigator 1 Boehringer Ingelheim International GmbH $4.50 02/28/2025 Non-covered Recipient Entity
Centricity Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220726031
Principal investigator 1 Boehringer Ingelheim International GmbH $4.50 02/28/2025 Non-covered Recipient Entity
Centricity Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220726033
Principal investigator 1 Boehringer Ingelheim International GmbH $21.43 02/28/2025 Non-covered Recipient Entity
Centricity Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220726035
Principal investigator 1 Boehringer Ingelheim International GmbH $33.71 02/28/2025 Non-covered Recipient Entity
Centricity Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220726037
Principal investigator 1 ModernaTX, Inc. $208.00 02/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007509
Principal investigator 1 ModernaTX, Inc. $6,802.40 02/27/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978806
Principal investigator 1 ModernaTX, Inc. $3,521.76 02/27/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978828
Principal investigator 1 ModernaTX, Inc. $6,392.76 02/27/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978842
Principal investigator 1 ModernaTX, Inc. $31,047.84 02/27/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978860
Principal investigator 1 ModernaTX, Inc. $46,933.74 02/27/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978862
Principal investigator 1 ModernaTX, Inc. $15,108.48 02/27/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978864
Principal investigator 1 ModernaTX, Inc. $19,784.70 02/27/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978878
Principal investigator 1 ModernaTX, Inc. $19,162.32 02/27/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978900
Principal investigator 1 ModernaTX, Inc. $17,804.80 02/27/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007499
Principal investigator 1 ModernaTX, Inc. $31,658.90 02/27/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007513
Principal investigator 1 ModernaTX, Inc. $16,645.20 02/27/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007521
Principal investigator 1 SANOFI PASTEUR INC. $7,854.80 02/26/2025 Non-covered Recipient Entity
Cr Services Acquisition Us Llc
A Phase 3, Randomized, Modified Double-blind, 2-arm Study to Evaluate the Immunogenicity and Safety of High-Dose Inactivated Influenza Vaccine (IIV-HD) Compared With a Standard-dose Inactivated Influenza Vaccine (IIV-SD) in Participants 50 Through 64 Years of Age. No dispute reported 06/30/2026 1226087972
Principal investigator 1 Boehringer Ingelheim International GmbH $116.60 02/25/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770875
Principal investigator 1 Boehringer Ingelheim International GmbH $79.92 02/25/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770877
Principal investigator 1 Boehringer Ingelheim International GmbH $11.04 02/25/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770879
Principal investigator 1 ModernaTX, Inc. $13,486.20 02/21/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252978914
Principal investigator 1 Novo Nordisk AS $9,202.05 02/21/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH
NN9536-7752 No dispute reported 06/30/2026 1213765559
Principal investigator 1 Novo Nordisk AS $300.00 02/21/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH
NN9536-7752 No dispute reported 06/30/2026 1213775228
Principal investigator 1 Novo Nordisk AS $6,612.00 02/21/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH COLUMBUS
NN9536-4512 No dispute reported 06/30/2026 1213837648
Principal investigator 1 ModernaTX, Inc. $40.30 02/19/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252978942
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $790.76 02/17/2025 Non-covered Recipient Entity
Aventiv Research, Inc.
A PHASE I, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND BIOMARKERS OF DONQ52 IN CELIAC DISEASE PATIENTS No dispute reported 06/30/2026 1211576455
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $682.76 02/17/2025 Non-covered Recipient Entity
Aventiv Research, Inc.
A PHASE I, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND BIOMARKERS OF DONQ52 IN CELIAC DISEASE PATIENTS No dispute reported 06/30/2026 1211576458
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $2,633.04 02/17/2025 Non-covered Recipient Entity
Aventiv Research, Inc.
A PHASE I, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND BIOMARKERS OF DONQ52 IN CELIAC DISEASE PATIENTS No dispute reported 06/30/2026 1211576464
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $1,779.98 02/17/2025 Non-covered Recipient Entity
Aventiv Research, Inc.
A PHASE I, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND BIOMARKERS OF DONQ52 IN CELIAC DISEASE PATIENTS No dispute reported 06/30/2026 1211576468
Principal investigator 1 PFIZER INC. $317.00 02/17/2025 Non-covered Recipient Entity
Centricity Research Columbus Ohio Multispecialty
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228707103
Principal investigator 1 PFIZER INC. $726.10 02/17/2025 Non-covered Recipient Entity
Centricity Research Columbus Ohio Multispecialty
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228707381
Principal investigator 1 PFIZER INC. $317.00 02/17/2025 Non-covered Recipient Entity
Centricity Research Columbus Ohio Multispecialty
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228840721
Principal investigator 1 PFIZER INC. $726.10 02/17/2025 Non-covered Recipient Entity
Centricity Research Columbus Ohio Multispecialty
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228840727
Principal investigator 1 Boehringer Ingelheim International GmbH $3,150.00 02/14/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726155
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 02/14/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726157
Principal investigator 1 Boehringer Ingelheim International GmbH $90.00 02/14/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726159
Principal investigator 1 ModernaTX, Inc. $403.20 02/14/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978756
Principal investigator 1 ModernaTX, Inc. $1,040.00 02/14/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978822
Principal investigator 1 ModernaTX, Inc. $70.81 02/14/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978886
Principal investigator 1 AstraZeneca UK Limited $6,500.00 02/12/2025 Non-covered Recipient Entity
AVENTIV RESEARCH
A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment No dispute reported 06/30/2026 1185547255
Principal investigator 1 ModernaTX, Inc. $400.00 02/12/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252978932
Principal investigator 1 PFIZER INC. $2,350.00 02/12/2025 Non-covered Recipient Entity
Centricity Research Columbus Ohio Multispecialty
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228707457
Principal investigator 1 ModernaTX, Inc. $88.79 02/10/2025 Non-covered Recipient Entity
AVENTIV RESEARCH, INC. COLUMBUS
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978760
Principal investigator 1 ModernaTX, Inc. $400.00 02/07/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978782
Principal investigator 1 ModernaTX, Inc. $856.80 02/07/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978844
Principal investigator 1 ModernaTX, Inc. $97.50 02/07/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978892
Principal investigator 1 ABBVIE INC. $16,332.30 02/06/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202449825
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $200.00 02/05/2025 Non-covered Recipient Entity
Aventiv Research, Inc.
A PHASE I, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND BIOMARKERS OF DONQ52 IN CELIAC DISEASE PATIENTS No dispute reported 06/30/2026 1211576472
Principal investigator 1 ModernaTX, Inc. $500.00 02/05/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252978948
Principal investigator 1 Novo Nordisk AS $4,698.00 02/05/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH COLUMBUS
NN9536-4512 No dispute reported 06/30/2026 1213749031
Principal investigator 1 Novo Nordisk AS $3,150.00 02/05/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH COLUMBUS
NN9536-4512 No dispute reported 06/30/2026 1213751545
Principal investigator 1 Eli Lilly and Company $84,702.00 02/04/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) No dispute reported 06/30/2026 1187880291
Principal investigator 1 Boehringer Ingelheim International GmbH $400.00 02/03/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726161
Principal investigator 1 PFIZER INC. $981.24 02/03/2025 Non-covered Recipient Entity
Centricity Research Columbus Ohio Multispecialty
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228814741
Principal investigator 1 PFIZER INC. $837.08 02/03/2025 Non-covered Recipient Entity
Centricity Research Columbus Ohio Multispecialty
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228814747
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 02/01/2025 Non-covered Recipient Entity
Centricity Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220726051
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770935
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770937
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770939
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770941
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770943
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 02/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770953
Principal investigator 1 Eli Lilly and Company $669.09 01/31/2025 Non-covered Recipient Entity
COLUMBUS CLINICAL RESEARCH INC
A STUDY OF TIRZEPATIDE (LY3298176) ONCE WEEKLY IN ADOLESCENT PARTICIPANTS WHO HAVE OBESITY, OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES No dispute reported 06/30/2026 1187876613
Principal investigator 1 Eli Lilly and Company $1,371.61 01/31/2025 Non-covered Recipient Entity
COLUMBUS CLINICAL RESEARCH INC
A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) No dispute reported 06/30/2026 1187878797
Principal investigator 1 Novo Nordisk AS $290.00 01/30/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH
NN9536-7752 No dispute reported 06/30/2026 1213752175
Principal investigator 1 Boehringer Ingelheim International GmbH $1,137.44 01/29/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726095
Principal investigator 1 ModernaTX, Inc. $252.00 01/29/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978846
Principal investigator 1 ModernaTX, Inc. $273.00 01/29/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252978924
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 01/27/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770867
Principal investigator 1 Boehringer Ingelheim International GmbH $0.62 01/27/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770869
Principal investigator 1 Boehringer Ingelheim International GmbH $0.58 01/27/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770871
Principal investigator 1 Boehringer Ingelheim International GmbH $3.48 01/27/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770873
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,436.00 01/27/2025 Non-covered Recipient Entity
Centricity Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220812196
Principal investigator 1 Eli Lilly and Company $6,156.64 01/27/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187878013
Principal investigator 1 ModernaTX, Inc. $5,174.64 01/27/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978758
Principal investigator 1 ModernaTX, Inc. $1,512.06 01/27/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978774
Principal investigator 1 ModernaTX, Inc. $850.30 01/27/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978778
Principal investigator 1 ModernaTX, Inc. $6,704.82 01/27/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978830
Principal investigator 1 ModernaTX, Inc. $5,621.76 01/27/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978850
Principal investigator 1 ModernaTX, Inc. $765.60 01/27/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978870
Principal investigator 1 ModernaTX, Inc. $3,193.72 01/27/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978884
Principal investigator 1 ModernaTX, Inc. $19,671.60 01/27/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007511
Principal investigator 1 ModernaTX, Inc. $4,347.20 01/27/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007517
Principal investigator 1 ModernaTX, Inc. $12,485.20 01/27/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007531
Principal investigator 1 ModernaTX, Inc. $17,659.20 01/27/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007535
Principal investigator 1 Boehringer Ingelheim International GmbH $12.43 01/22/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726061
Principal investigator 1 Boehringer Ingelheim International GmbH $1.92 01/22/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726063
Principal investigator 1 Boehringer Ingelheim International GmbH $1.92 01/22/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726067
Principal investigator 1 Boehringer Ingelheim International GmbH $1.92 01/22/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726073
Principal investigator 1 Boehringer Ingelheim International GmbH $1.92 01/22/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726079
Principal investigator 1 Boehringer Ingelheim International GmbH $1.92 01/22/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726081
Principal investigator 1 Boehringer Ingelheim International GmbH $1.92 01/22/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726083
Principal investigator 1 Boehringer Ingelheim International GmbH $90.00 01/22/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726093
Principal investigator 1 Boehringer Ingelheim International GmbH $12.48 01/22/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726099
Principal investigator 1 Boehringer Ingelheim International GmbH $1.92 01/22/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726101
Principal investigator 1 Boehringer Ingelheim International GmbH $1.92 01/22/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726103
Principal investigator 1 Boehringer Ingelheim International GmbH $1.92 01/22/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726107
Principal investigator 1 Boehringer Ingelheim International GmbH $1.92 01/22/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726109
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 01/22/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726111
Principal investigator 1 Boehringer Ingelheim International GmbH $24.23 01/22/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726113
Principal investigator 1 Boehringer Ingelheim International GmbH $1.92 01/22/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726115
Principal investigator 1 Boehringer Ingelheim International GmbH $1.92 01/22/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726119
Principal investigator 1 Boehringer Ingelheim International GmbH $1.92 01/22/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726121
Principal investigator 1 Boehringer Ingelheim International GmbH $12.48 01/22/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726127
Principal investigator 1 Boehringer Ingelheim International GmbH $1.92 01/22/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726129
Principal investigator 1 Boehringer Ingelheim International GmbH $1.92 01/22/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726131
Principal investigator 1 Boehringer Ingelheim International GmbH $12.48 01/22/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726137
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 01/22/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726139
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 01/22/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726143
Principal investigator 1 Boehringer Ingelheim International GmbH $1.92 01/22/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726145
Principal investigator 1 Boehringer Ingelheim International GmbH $1.92 01/22/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726147
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 01/22/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726153
Principal investigator 1 ModernaTX, Inc. $168.75 01/22/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ?65 Years of Age No dispute reported 06/30/2026 1252978792
Principal investigator 1 ModernaTX, Inc. $150.00 01/22/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ?65 Years of Age No dispute reported 06/30/2026 1252978820
Principal investigator 1 ModernaTX, Inc. $6,559.80 01/22/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252978938
Principal investigator 1 ModernaTX, Inc. $1,091.12 01/22/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007485
Principal investigator 1 SANOFI PASTEUR INC. $116,055.40 01/22/2025 Non-covered Recipient Entity
Cr Services Acquisition Us Llc
A Phase 3, Randomized, Modified Double-blind, 2-arm Study to Evaluate the Immunogenicity and Safety of High-Dose Inactivated Influenza Vaccine (IIV-HD) Compared With a Standard-dose Inactivated Influenza Vaccine (IIV-SD) in Participants 50 Through 64 Years of Age. No dispute reported 06/30/2026 1226087966
Principal investigator 1 Boehringer Ingelheim International GmbH $68.04 01/16/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726057
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $46,410.00 01/16/2025 Non-covered Recipient Entity
Centricity Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220812194
Principal investigator 1 AstraZeneca Pharmaceuticals LP $22,801.00 01/15/2025 Non-covered Recipient Entity
CR SERVICES ACQUSITION US, LLC
a phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like particle VLP vaccine in adults 60 years of age and older No dispute reported 06/30/2026 1185547253
Principal investigator 1 Boehringer Ingelheim International GmbH $250.00 01/15/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726069
Principal investigator 1 Boehringer Ingelheim International GmbH $480.00 01/15/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726151
Principal investigator 1 ModernaTX, Inc. $500.00 01/15/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252978946
Principal investigator 1 Eli Lilly and Company $222,598.90 01/07/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A STUDY OF TIRZEPATIDE (LY3298176) ONCE WEEKLY IN ADOLESCENT PARTICIPANTS WHO HAVE OBESITY, OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES No dispute reported 06/30/2026 1187878623
Principal investigator 1 Eli Lilly and Company $41,585.38 01/07/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1187878625
Principal investigator 1 Eli Lilly and Company $340,896.55 01/07/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187883796
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $66.00 01/06/2025 Non-covered Recipient Entity
Centricity Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220812192
Principal investigator 1 AstraZeneca Pharmaceuticals LP $79,946.37 01/03/2025 Non-covered Recipient Entity
CR SERVICES ACQUSITION US, LLC
a phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease ckd progression in participants with ckd and high blood pressure No dispute reported 06/30/2026 1185547251
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 01/02/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726059
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 01/02/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726065
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 01/02/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726071
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 01/02/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726075
Principal investigator 1 Boehringer Ingelheim International GmbH $400.00 01/02/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726077
Principal investigator 1 Boehringer Ingelheim International GmbH $400.00 01/02/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726085
Principal investigator 1 Boehringer Ingelheim International GmbH $400.00 01/02/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726087
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 01/02/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726089
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 01/02/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726091
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 01/02/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726097
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 01/02/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726105
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 01/02/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726117
Principal investigator 1 Boehringer Ingelheim International GmbH $400.00 01/02/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726123
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 01/02/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726125
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 01/02/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726133
Principal investigator 1 Boehringer Ingelheim International GmbH $400.00 01/02/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726135
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 01/02/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726141
Principal investigator 1 Boehringer Ingelheim International GmbH $400.00 01/02/2025 Non-covered Recipient Entity
Centricity Research
Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis No dispute reported 06/30/2026 1220726149
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 01/01/2025 Non-covered Recipient Entity
Centricity Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220726021
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770925
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770927
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770929
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770931
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770933
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 01/01/2025 Non-covered Recipient Entity
Aventiv Research Dublin
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220770951
Principal investigator 1 Novartis Pharmaceuticals Corporation $20,790.19 01/01/2025 Non-covered Recipient Entity
AVENTIV RESEARCH GROVE CITY
A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal and Open-label Extension Study Followed by Long-term Open-label Treatment Cycles to Assess the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Chronic Spontaneous U No dispute reported 06/30/2026 1190309778
Principal investigator 1 Novartis Pharmaceuticals Corporation $815.52 01/01/2025 Non-covered Recipient Entity
CARE SERVICES ACQUISITION US
A One Month, Investigator and Participant Blinded Study to Investigate the Efficacy and Safety of Remibrutinib (LOU064) at Multiple Dose Levels in Adult Participants With Peanut Allergy No dispute reported 06/30/2026 1190309850
Principal investigator 1 PFIZER INC. $6,650.00 01/01/2025 Non-covered Recipient Entity
CR Services Acquisition US LLC dba Centricity Research
A PHASE 12 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA COVID19 VACCINE AND A RECOMBINANT INFLUENZA VACCINE ADMINISTERED AS A SINGLE INJECTION IN HEALTHY ADULTS 50 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1228863500